Correction to ‘Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain’

Mazagatos, C., Mendioroz, J., Rumayor, M., Gallardo García, V., Álvarez Río, V., Cebollada Gracia, A., Batalla Rebollo, N., Barranco Boada, M., Pérez-Martínez, O., Lameiras Azevedo, A., López González-Coviella, N., Castrillejo, D., Fernández Ibáñez, A., Giménez Duran, J., Ramírez Córcoles, C., Ramos Marín, V., Larrauri, A., Monge, S. and (2024), Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain. Influenza Other Respi Viruses, 18: e13294. https://doi.org/10.1111/irv.13294

In the article, there was an error in the denominators reported by one of the regions contributing to the national SiVIRA surveillance, affecting both the primary care and hospital catchment populations. This error affects the calculation of national SARI hospitalisation rates for the 2022–2023 and 2023–2024 seasons, as well as all subsequent estimates of RSV-specific proxy hospitalisation rates and the observed and expected number of RSV hospitalisations. Although Figures 1 and 2 and the published estimates in Table 1 have changed, this correction does not change the overall study conclusions.

The corrected Table 1 is as follows:

The corrected Figures 1 and 2 are as follows:

The text should be corrected every time these estimates are mentioned: In Section 2.3, ‘Estimated Impact of Nirsevimab: Comparing Observed and Expected’, the text in the second paragraph ‘We estimated that, during weeks 40/2023 to 8/2024, the administration of nirsevimab reduced RSV hospitalisations in < 1-year-olds by between 74% and 75%, depending on the scaling factor used. This resulted in between 9364 and 9875 averted RSV hospitalisations in this group and period’ was incorrect and should read as ‘We estimated that, during weeks 40/2023 to 8/2024, the administration of nirsevimab reduced RSV hospitalisations in < 1-year-olds by between 71% and 77%, depending on the scaling factor used. This resulted in between 7510 and 10,213 averted RSV hospitalisations in this group and period’.

In the discussion section, fourth paragraph, the text ‘Our study has estimated a 74%–75% relative reduction in the risk of RSV hospitalisation …’ was incorrect and should read as ‘Our study has estimated a 71%–77% relative reduction in the risk of RSV hospitalisation …’.

We apologise for this error.